ClinicalTrials.gov
public full text
Public Domain
WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC
This is a multi-center, prospective, open-label, phase II trial. Patients with suspected advanced ovarian cancer planned to undergo diagnostic laparoscopy for histologic confirmation and evaluation of disease spread will be registered into the trial after providing a 1st written informed consent.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC#902141
- Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment#432889
- Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC#1172719
- TAX + Carboplatin or Cisplatin 1st Line Post-Surgery Ovarian#1057479
- Carboplatin With or Without Thalidomide in Treating Patients With Ovarian Epithelial Cancer#1102835
Record · ID 1174298
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive